Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBIT Margin (2021 - 2025)

Historic EBIT Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 13.28%.

  • Kiniksa Pharmaceuticals International's EBIT Margin rose 218900.0% to 13.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.38%, marking a year-over-year increase of 132100.0%. This contributed to the annual value of 10.78% for FY2024, which is 14500.0% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported EBIT Margin of 13.28% as of Q3 2025, which was up 218900.0% from 12.86% recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's EBIT Margin ranged from a high of 46.82% in Q3 2022 and a low of 526.41% during Q2 2021
  • In the last 5 years, Kiniksa Pharmaceuticals International's EBIT Margin had a median value of 12.18% in 2024 and averaged 62.63%.
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 4546100bps in 2022, then crashed by -631200bps in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBIT Margin (Quarter) stood at 192.75% in 2021, then skyrocketed by 98bps to 4.08% in 2022, then surged by 102bps to 0.1% in 2023, then plummeted by -16315bps to 15.75% in 2024, then skyrocketed by 184bps to 13.28% in 2025.
  • Its EBIT Margin was 13.28% in Q3 2025, compared to 12.86% in Q2 2025 and 9.63% in Q1 2025.